{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.0","upperLimit":"37.7","value":"30.9"},{"groupId":"OG001","lowerLimit":"25.8","upperLimit":"39.1","value":"32.4"},{"groupId":"OG002","lowerLimit":"34.3","upperLimit":"49.0","value":"41.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"188"},{"groupId":"OG002","value":"173"}],"units":"Participants"}],"description":"Overall objective tumor response was defined as having a partial response (PR) or complete response (CR) according to the RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Docetaxel (TXT) 75 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG000","title":"Docetaxel 75 mg/m^2"},{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG001","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG002","title":"Cabazitaxel 25 mg/m^2"}],"paramType":"NUMBER","populationDescription":"Analysis was performed on ITT population. Number of participants analyzed=participants with measurable disease at baseline and at least one valid post-baseline value analyzed for specified outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline up to DP or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)","title":"Percentage of Participants With Overall Objective Tumor Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}